[go: up one dir, main page]

EP2477606A1 - Préparations pharmaceutique solides à dissolution rapide contenant des copolymères amphiphiles à base de polyéthers en combinaison avec des polymères hydrophiles - Google Patents

Préparations pharmaceutique solides à dissolution rapide contenant des copolymères amphiphiles à base de polyéthers en combinaison avec des polymères hydrophiles

Info

Publication number
EP2477606A1
EP2477606A1 EP10754933A EP10754933A EP2477606A1 EP 2477606 A1 EP2477606 A1 EP 2477606A1 EP 10754933 A EP10754933 A EP 10754933A EP 10754933 A EP10754933 A EP 10754933A EP 2477606 A1 EP2477606 A1 EP 2477606A1
Authority
EP
European Patent Office
Prior art keywords
dosage forms
polymers
copolymers
forms according
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10754933A
Other languages
German (de)
English (en)
Inventor
Karl Kolter
Dejan Djuric
Stefan Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Priority to EP10754933A priority Critical patent/EP2477606A1/fr
Publication of EP2477606A1 publication Critical patent/EP2477606A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Definitions

  • the present invention relates to solid pharmaceutical compositions containing poorly water-soluble active ingredients and amphiphilic copolymers obtained by polymerizing vinyl acetate and N-vinyl lactams in the presence of a polyether, in combination with hydrophilic polymers capable of improving the stability of the formulation and / or to influence the release of the biologically active substance. Furthermore, the invention relates to processes for the preparation of these preparations and their use.
  • the corresponding copolymers based on polyethers act as solubilizers for the active substances which are sparingly soluble in water.
  • Solubilization is understood to mean the solubilization of substances which are soluble or insoluble in a particular solvent, in particular water, by surface-active compounds, the solubilizers. Such solubilizers are capable of converting poorly water-soluble or water-insoluble substances into clear, at most opalescent aqueous solutions, without the chemical structure of these substances undergoing any change.
  • solubilizates prepared are characterized in that the sparingly water-soluble or water-insoluble substance is colloidally dissolved in the molecular associates of the surface-active compounds which form in aqueous solution, for example hydrophobic domains or micelles.
  • the resulting solutions are stable or metastable single-phase systems that appear optically clear to opalescent.
  • the bioavailability and thus the effect of drugs can be increased by the use of solubilizers.
  • solid solution refers to a state in which a substance is dispersed colloidally or, ideally, molecularly dispersed in a solid matrix such as a polymer matrix .
  • solid solutions for example, when used in solid pharmaceutical dosage forms of a poorly soluble drug to an improved release of the drug.
  • An important requirement of such solid solutions is that they are stable even when stored for a long time, ie, that the active ingredient does not crystallize out.
  • the capacity of the solid solution in other words the ability to form stable solid solutions with the highest possible active ingredient contents, is of importance.
  • WO 2007/051743 discloses the use of amphiphilic water-soluble or water-dispersible copolymers of N-vinyllactam, vinyl acetate and polyethers as solubilizers for pharmaceutical, cosmetic, food-processing, agrotechnical or other technical applications. It is generally described that the corresponding graft polymers in the
  • Vinyllactam, vinyl acetate and polyethers can be melted in the extruder and mixed with powdered or liquid ingredients, wherein the extrusion is described at temperatures well below the melting point of the active ingredient.
  • mixing the molten graft polymer with powdered or liquid drugs does not always provide a satisfactorily high and stable drug loading.
  • the achievement of a stable X-ray amorphous state of the active ingredient does not always succeed satisfactorily. It was an object of the present invention to find improved preparations of substances which are sparingly soluble in water and, with good bioavailability, permit a targeted adjustment of the release and, moreover, have improved properties with respect to stability to higher atmospheric moisture.
  • amphiphilic copolymers can be obtained by free-radically initiated polymerization of a mixture of i) 30 to 80% by weight of N-vinyllactam,
  • preferred copolymers are obtained from: i) 30 to 70% by weight of N-vinyllactam
  • Copolymers particularly preferably used are obtainable from: i) 40 to 60% by weight of N-vinyllactam
  • Very particularly preferably used copolymers are obtainable from i) 50 to 60 wt .-% N-vinyl lactam
  • Suitable N-vinyllactam are N-vinylcaprolactam or N-vinylpyrrolidone or mixtures thereof. Preference is given to using N-vinylcaprolactam.
  • the graft is polyether.
  • Suitable polyethers are preferably polyalkylene glycols.
  • the polyalkylene glycols may have molecular weights of from 1000 to 100,000 D [daltons], preferably from 1500 to 35,000 D, more preferably from 1,500 to 10,000 D. The molecular weights are determined on the basis of the measured according to DIN 53240 OH number.
  • Particularly preferred polyalkylene glycols are polyethylene glycols.
  • polypropylene glycols polytetrahydrofurans or polybutylene glycols obtained from 2-ethyloxirane or 2,3-dimethyloxirane.
  • Suitable polyethers are also random or block copolymers of polyalkylene glycols obtained from ethylene oxide, propylene oxide and butylene oxides, such as, for example, polyethylene glycol-polypropylene glycol block copolymers.
  • the block copolymers may be of the AB or ABA type.
  • the preferred polyalkylene glycols also include those which are alkylated at one or both OH end groups.
  • Suitable alkyl radicals are branched or unbranched C to C22-alkyl radicals, preferably C 1 -C 6 -alkyl radicals, for example methyl, ethyl, n-butyl, isobutyl, pentyl, hexyl, octyl, nonyl, decyl , Dodecyl, tridecyl or octadecyl radicals.
  • the solubilizing copolymers are used in combination with other polymers which are suitable for influencing the release of the biologically active substance.
  • the degree of release-influencing usually depends on the concentration of the release-controlling polymer.
  • the addition of hydrophilic polymers can influence the rate of disintegration of the resulting extrudates during release. By increasing the hydrophilicity, faster wetting and faster disintegration in the release can be achieved.
  • Hydrophilic polymers with low molecular weights are particularly suitable for this purpose ( ⁇ 100,000 daltons). Hydrophilic polymers of higher molecular weight (> 100,000 daltons).
  • the hydrophilic polymers are usually water-soluble, at least in a certain pH range. Water-soluble in this context means that dissolve at 20 ° C at least 0.1 g in 1 ml.
  • Suitable hydrophilic polymers are, for example: polyvinylpyrrolidones having K values of 12 to 90, N-vinylpyrrolidone copolymers, for example copolymers with vinyl esters such as vinyl acetate or vinyl propionate, in particular copolymers of N-vinylpyrrolidone and vinyl acetate in a weight ratio of 60:40, polyvinyl alcohols, hydroxyalkylated cellulose derivatives such as hydroxypropylcellulose (HPC) or hydroxypropylmethylcellulose (HPMC), hydroxyalkylated and carboxyalkylated cellulose derivatives, acrylic acid-methacrylic acid copolymers.
  • N-vinylpyrrolidone copolymers for example copolymers with vinyl esters such as vinyl acetate or vinyl propionate, in particular copolymers of N-vinylpyrrolidone and vinyl acetate in a weight ratio of 60:40
  • polyvinyl alcohols hydroxyalkylated
  • polyethylene glycols having average molecular weights of 1000 to 6000.
  • graft polymers of polyethylene glycol and polyvinyl alcohol units such as are commercially available as Kollicoat® IR, from BASF, or mixtures of such graft polymers with polyvinyl alcohol.
  • the term water-insoluble or sparingly soluble according to DAB 9 is used.
  • DAB 9 German Pharmacopoeia
  • the solubility of substances is classified as follows: slightly soluble (soluble in 30 to 100 parts solvent); poorly soluble (soluble in 100 to 1000 parts of solvent); practically insoluble (soluble in more than 10,000 parts of solvent), in each case based on a part to be dissolved at 20 ° C.
  • the preparation of the solid preparations can be carried out by methods known per se.
  • all ingredients of the preparations are first brought together in a suitable solvent in solution and the solvent is then removed.
  • This can be done via all kinds of drying processes, e.g. via spray drying, fluidized bed drying, drying using supercritical gases, freeze drying, evaporation.
  • the solid preparations are prepared by extrusion.
  • the polymers can be fed to the extruder both in powder form and in the form of solutions or dispersions.
  • the dispersions or solutions of the polymer can be converted into solid form by removing the dispersion or solvent in the extruder in the molten state and cooling the melt.
  • the melt thus obtained can then be cooled and granulated.
  • a so-called hot break or cooling takes place under air or inert gas, for example, on a Teflon or chain belt and subsequent granulation of the cooled melt strand.
  • cooling may also take place in a solvent in which the polymers are not significantly soluble.
  • the customary extruder types known to the person skilled in the art are suitable for the process according to the invention. These usually comprise a housing, a drive unit with gearbox and a process unit which consists of the extruder shaft (s) equipped with the screw elements, in which case modular construction is assumed.
  • the extruder consists of several sections, each of which can be assigned to specific process units. Each of these sections consists of one or more cylinders (cylinder blocks) as the smallest independent unit - and the associated screw sections with the process elements corresponding screw elements.
  • the individual cylinders should be heated. Furthermore, the cylinders can also be designed for cooling, for example for cooling with water.
  • the individual cylinder blocks can preferably be heated and cooled independently of each other so that different temperature zones can also be set along the extrusion direction
  • the extruder is advantageously designed as a co-rotating twin-screw extruder.
  • the screw configuration can vary in severity depending on the product.
  • the screw configuration can be used with the usual variable components such as conveying elements, kneading elements, backflow elements and the like depending on the composition of the formulation to the appropriate needs.
  • Suitable twin-screw extruders may have a screw diameter of 16 to 70 mm and a length of 25 to 40 D.
  • the entire extruder is constructed of cylinder blocks, which are individually tempered.
  • the first two cylinders can be tempered for better material intake.
  • a constant temperature is preferably set, which is to be selected specifically for the material and in particular depends on the melting point of the active substance used and the glass transition temperature of the polymer.
  • the resulting product temperature is usually dependent on the degree of shear of the screw element used and may sometimes be 20-30 ° C higher than the set cylinder temperature.
  • a degassing zone can be connected downstream, which is advantageously operated at ambient pressure.
  • the round nozzles used can have a diameter of 0.5 to 5 mm.
  • Other nozzle shapes, such as slot dies can also be used, especially if a larger material throughput is desired.
  • the resulting extrudate strands can be processed into granules with a granulator and these in turn can be further comminuted (ground) into a powder.
  • the granules or powder can be filled into capsules or pressed into tablets using conventional tableting excipients. In this case, further release-controlling adjuvants can also be used.
  • water, organic solvents, buffer substances or plasticizers are suitable for this purpose.
  • water or volatile alcohols are suitable for this purpose.
  • the amounts of solvent or plasticizer are usually between 0 and 30% of the extrudable mass.
  • the water or solvent can already be removed by a degassing point in the extruder at atmospheric pressure or by applying a vacuum. Alternatively, these components evaporate as the extrudate exits the extruder and the pressure reduces to normal pressure. In the case of less volatile components, the extrudate can be post-dried accordingly.
  • thermoplastic mass is calendered into a tablet-like compressed product which represents the final administration form.
  • other constituents for example polymers for adjusting the glass transition. transition temperature and the melt viscosity, disintegrants, solubilizers, plasticizers, dyes, flavorings, sweeteners, etc. already before or during the extrusion add. In principle, these substances can also be used if the extrudate is first comminuted and then pressed into tablets.
  • water-soluble polymers of high glass transition temperature e.g. Polyvinylpyrrolidone with K values of 17 to 120, hydroxyalkyl or hydroxalkyl can be used. Too high a glass transition temperature of the formulation can be lowered by adding plasticizers.
  • plasticizers are suitable, which are also used for pharmaceutical coatings, such. Triethyl citrate, tri- butyl citrate, acetyl tributyl citrate, triacetin, propylene glycol, polyethylene glycol 400, dibutyl sebacate, glycerol monostearate, lauric acid, cetylstearyl alcohol.
  • surfactants which reduce the melt viscosity and thus the extrusion temperature can also be incorporated into the formulations. These substances can also positively influence the possible crystallization and bring about a better wetting of the formulation and a faster dissolution.
  • Suitable substances are ionic and nonionic surfactants such as, for example, Solutol® HS 15 (Macrogol 15-hydroxystearate), Tween® 80, polyoxyethylated fatty acid derivatives such as Cremophor® RH40 (polyoxyl 40 Hydrogenated Castor Oil, USP), Cremophor EL (Polyoxy 35 Castor Oil , USP), poloxamers, docusate sodium or sodium lauryl sulfate.
  • the still plastic mixture is preferably extruded through a die, cooled and comminuted.
  • all common techniques known for this, such as hot or cold cutting, are suitable in principle.
  • the extrudate is cut off, for example with rotating knives or with an air jet and then cooled with air or under inert gas.
  • extrudate as a melt strand on a cooled strip (stainless steel, Teflon, chain strip) and granulate after solidification.
  • a cooled strip stainless steel, Teflon, chain strip
  • the extrudate can optionally be ground.
  • the preparations are obtained as free-flowing and flowable water-soluble powders. Particle sizes of 20 to 250 ⁇ m are preferably set.
  • the formulations according to the invention have a significantly improved stability, that is to say the active substance remains in a molecularly dispersed or amorphous state in the formulation and does not crystallize out. As a result, the release properties do not change over time.
  • the preparations according to the invention have a higher bioavailability of the active ingredient than the preparations without water-soluble polymer.
  • the formulations obtained by the process according to the invention can be used in principle in all areas in which only sparingly soluble or insoluble substances in water should either be used in aqueous preparations or should have their effect in an aqueous environment.
  • the term "sparingly soluble in water” also encompasses practically insoluble substances and means that a solution of the substance in water requires at least 30 to 100 g of water per g of substance at 20 ° C. In the case of practically insoluble substances, at least 10,000 g Water per g of substance needed.
  • Also suitable as the sparingly soluble substances to be solubilized are also dyes such as inorganic or organic pigments.
  • Suitable biologically active substances according to the invention are, in principle, all solid active compounds which have a melting point which is below the decomposition point under extrusion conditions of the copolymers.
  • the copolymers can generally be extruded at temperatures up to 260 ° C. The lower temperature limit depends on the composition of the mixtures to be extruded and the sparingly soluble substances to be administered in each case.
  • the pharmaceutical active ingredients used are water-insoluble or sparingly soluble substances according to the already mentioned definition according to DAB 9.
  • the active ingredients can come from any indication.
  • Examples include benzodiazepines, antihypertensives, vitamins, cytostatic drugs - especially taxol, anesthetics, neuroleptics, antidepressants, antiviral agents such as anti-HIV agents, antibiotics, antimycotics, anti-dementia, fungicides, chemotherapeutics, urologics, antiplatelet agents, sulfonamides, anticonvulsants, Hormones, immunoglobulins, serums, thyroid therapeutics, psychotropic drugs, Parkinson's and other antihyperkinetics, ophthalmics, neuropathy preparations, calcium metabolism regulators, muscle relaxants, anesthetics, lipid-lowering agents, liver therapeutics, coronary agents, cardiacs, immunotherapeutics, regulatory peptides and their inhibitors, hypnotics, sedatives, gynecologics, gout remedies , Fibrinolytics, enzyme preparations and transport proteins, enzyme inhibitors, emetics, circulation-promoting agents, di
  • Particularly preferred of the abovementioned pharmaceutical preparations are those which are orally administrable formulations.
  • the content of solubilizer according to the invention in the pharmaceutical preparation is, depending on the active ingredient, in the range of 1 to 75 wt .-%, preferably 5 to 60 wt .-%, particularly preferably 5 to 50 wt .-%.
  • the extrudates can be mixed with conventional pharmaceutical excipients.
  • fillers e.g. inorganic fillers such as oxides of magnesium, aluminum, silicon, titanium or calcium carbonate, calcium or magnesium phosphates or organic fillers such as lactose, sucrose, sorbitol, mannitol may be added.
  • Suitable plasticizers are, for example, triacetin, triethyl citrate, glycerol monostearate, low molecular weight polyethylene glycols or poloxamers.
  • HLB value hydrophilic lipophilic balance
  • ethoxylated hydrogenated castor oil Cremophor® RH 40
  • ethoxylated castor oil Cremophor eL
  • Polysorbate 80 poloxamers or sodium lauryl sulfate.
  • stearates of aluminum, calcium, magnesium and tin, as well as magnesium silicate, silicones and the like can be used.
  • talc or colloidal silica can be used as flow agents.
  • Suitable binders are, for example, microcrystalline cellulose.
  • Crosslinked polyvinylpyrrolidone or cross-linked sodium carboxymethyl starch can be used as disintegrating agents.
  • Stabilizers may be ascorbic acid or tocopherol.
  • Dyes are e.g. Iron oxides, titanium dioxide, triphenylmethane dyes, azo dyes, quinoline dyes, indigotine dyes, carotenoids to dye the dosage forms, opacifying agents such as titanium dioxide or talc to increase the light transmission and to save dyes.
  • the preparations according to the invention are also suitable for use in the food industry, for example for the incorporation of nutrients, auxiliaries or additives which are sparingly soluble in water or insoluble in water, for example fat-soluble vitamins or carotenoids. Examples include drinks colored with carotenoids.
  • the use of the preparations according to the invention in agrochemicals may include, inter alia, formulations containing pesticides, herbicides, fungicides or insecticides, especially those preparations of crop protection agents used as spray or pouring broths. With the aid of the method according to the invention so-called solid solutions with sparingly soluble substances can be obtained. Solid solutions according to the invention are systems in which no crystalline components of the sparingly soluble substance are observed.
  • Visual examination of the stable solid solutions reveals no amorphous constituents.
  • the visual inspection can be done with a light microscope both with and without a polarizing filter at 40x magnification.
  • the preparations can also with the aid of XRD (X-ray diffraction) and
  • the preparations obtained by the process according to the invention are amorphous, which means that the crystalline proportions of the biologically active substance are less than 5% by weight.
  • the amorphous state is checked by DSC or XRD. Such an amorphous state may also be referred to as an amorphous state.
  • the process of the invention allows the production of stable preparations with high drug loading and good stability with respect to the amorphous state of the sparingly soluble substance.
  • the inventive method allows the production of stable preparations with high drug loading.
  • the formulations can be gela gert at high humidity without the active ingredient crystallized.
  • the template was heated without the subset of feed 2 under an atmosphere of IS to 77 ° C.
  • the portion of feed 2 was added and grafted on for 15 min.
  • feed 1 was added in 5 h and feed 2 in 2 h.
  • the reaction mixture was postpolymerized for a further 3 hours. After postpolymerization, the solution was adjusted to a solids content of 50% by weight.
  • Feed 2 10.44 g of tert-butyl perpivalate (75% strength by weight in aliphatic mixture)
  • the K value was 16, measured 1 wt .-% strength in ethanol
  • the twin-screw extruder used to prepare the formulations described in the Examples below had a screw diameter of 16 mm and a length of 40D.
  • the entire extruder was made up of 8 individually heatable cylinder blocks. The first two cylinders were tempered at 20 ° C or at 70 ° C for better material intake. From the third cylinder a constant temperature was set
  • the prepared solid solutions were analyzed for crystallinity and amorphicity using XRD (X-ray diffractometry) and DSC (Differential Scanning Calorimetry) using the following equipment and conditions:
  • Measuring instrument Diffractometer D 8 Advance with 9-fold sample changer (Fa.Bruker / AXS) Type of measurement: ⁇ - ⁇ Geometry in reflection
  • the drug release was carried out according to USP apparatus (paddle method) 2, 37 ° C, 50 rpm (BTWS 600, Pharmatest).
  • the extrudate strands were cut to a length of 3 mm by means of a granulator and filled into hard gelatine capsules.
  • the detection of the released active ingredient was carried out by UV spectroscopy (Lamda-2, Perkin Elmer)
  • the solid solutions were analyzed by XRD and by DSC and found to be amorphous.
  • the release of the active substance in phosphate buffer pH 6.8 was 27% after 2 h, after 10 h 82% of the active ingredient originally used was released.
  • Zone temperature 1st cylinder 20 ° C; 2nd cylinder: 40 ° C
  • Zone temperature 1st cylinder 20 ° C; 2nd cylinder: 40 ° C
  • Nozzle diameter 3mm By adding PEG 1500, the extrusion temperature could be lowered to 130 ° C, which had no influence on the solid solution.
  • the transparent solid solutions were analyzed by XRD and by DSC and found to be amorphous. After 1 h in 0.1 normal HCl, 95% active ingredient was released.
  • Zone temperature 1st cylinder 20 ° C; 2nd cylinder: 40 ° C
  • Zone temperature 1st cylinder 20 ° C; 2nd cylinder: 40 ° C
  • Nozzle diameter 3mm The solid solutions were analyzed by XRD and DSC and found to be amorphous. The addition of Kollidon 17PF resulted in a faster dissolution of the granules during release. After 1 h in 0.1 normal HCl, 80% active ingredient was released.
  • Zone temperature 1st cylinder 20 ° C; 2nd cylinder: 40 ° C
  • Zone temperature 1st cylinder 20 ° C; 2nd cylinder: 40 ° C
  • Zone temperature 1st cylinder 20 ° C; 2nd cylinder: 40 ° C

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formes posologiques contenant des préparations de substances actives peu solubles dans l'eau dans une matrice polymérique composée de copolymères de polyéther amphiphiles et d'au moins un polymère hydrophile, la substance active peu soluble dans l'eau étant présente dans la matrice polymérique sous forme amorphe.
EP10754933A 2009-09-18 2010-09-17 Préparations pharmaceutique solides à dissolution rapide contenant des copolymères amphiphiles à base de polyéthers en combinaison avec des polymères hydrophiles Withdrawn EP2477606A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10754933A EP2477606A1 (fr) 2009-09-18 2010-09-17 Préparations pharmaceutique solides à dissolution rapide contenant des copolymères amphiphiles à base de polyéthers en combinaison avec des polymères hydrophiles

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09170702 2009-09-18
PCT/EP2010/063735 WO2011033085A1 (fr) 2009-09-18 2010-09-17 Préparations pharmaceutique solides à dissolution rapide contenant des copolymères amphiphiles à base de polyéthers en combinaison avec des polymères hydrophiles
EP10754933A EP2477606A1 (fr) 2009-09-18 2010-09-17 Préparations pharmaceutique solides à dissolution rapide contenant des copolymères amphiphiles à base de polyéthers en combinaison avec des polymères hydrophiles

Publications (1)

Publication Number Publication Date
EP2477606A1 true EP2477606A1 (fr) 2012-07-25

Family

ID=43017117

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10754933A Withdrawn EP2477606A1 (fr) 2009-09-18 2010-09-17 Préparations pharmaceutique solides à dissolution rapide contenant des copolymères amphiphiles à base de polyéthers en combinaison avec des polymères hydrophiles

Country Status (6)

Country Link
US (1) US20120202894A1 (fr)
EP (1) EP2477606A1 (fr)
JP (1) JP2013505222A (fr)
CN (1) CN102655857A (fr)
BR (1) BR112012006056A2 (fr)
WO (1) WO2011033085A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9032390B2 (en) * 2008-07-29 2015-05-12 Qualcomm Incorporated Framework versioning
US8636929B2 (en) 2010-05-21 2014-01-28 Basf Se Nanoporous foamed active compound-containing preparations based on pharmaceutically acceptable thermoplastically workable polymers
US8715729B2 (en) 2010-12-22 2014-05-06 Basf Se Rapidly disintegrating, solid coated dosage form
US20160000720A1 (en) * 2013-02-14 2016-01-07 Aurobindo Pharma Limited Pharmaceutical compositions comprising Tadalafil
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
JP6968062B6 (ja) * 2015-10-23 2021-12-15 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se 発香性物質及び香味物質とビニルラクタムポリマーとの固溶体
CA3073195A1 (fr) 2017-08-15 2019-02-21 Nephron Pharmaceuticals Corporation Composition de nebulisation aqueuse

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010112489A2 (fr) * 2009-03-31 2010-10-07 Basf Se Procédé de production de préparations de substances difficilement solubles dans l'eau

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050181055A1 (en) * 2003-10-08 2005-08-18 Mathur Rajeev S. Pharmaceutical compositions of quinapril
JP2007517015A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬物、ポロキサマーおよび安定化ポリマーの安定化された医薬用固体組成物
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
US20100204425A1 (en) 2007-07-26 2010-08-12 Basf Se Process for preparing copolymers obtained by graft polymerization in solution and based on polyethers in solid form
CN102164583B (zh) 2008-09-25 2013-11-06 巴斯夫欧洲公司 聚醚基和乙烯基单体基共聚物作为包含固体活性成分的剂型用粘合剂的用途
WO2010130728A2 (fr) 2009-05-13 2010-11-18 Basf Se Préparations pharmaceutiques solides contenant des copolymères à base de polyéthers en association avec des polymères peu solubles dans l'eau

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010112489A2 (fr) * 2009-03-31 2010-10-07 Basf Se Procédé de production de préparations de substances difficilement solubles dans l'eau

Also Published As

Publication number Publication date
BR112012006056A2 (pt) 2016-03-29
CN102655857A (zh) 2012-09-05
US20120202894A1 (en) 2012-08-09
WO2011033085A1 (fr) 2011-03-24
JP2013505222A (ja) 2013-02-14

Similar Documents

Publication Publication Date Title
EP2429492B1 (fr) Préparations pharmaceutiques solides contenant des copolymères à base de polyéthers en association avec des polymères peu solubles dans l'eau
EP2413907B1 (fr) Procédé de production de préparations de substances difficilement solubles dans l'eau
EP2229151B1 (fr) Sels de principes actifs ayant des contre-ions polymères
EP2477606A1 (fr) Préparations pharmaceutique solides à dissolution rapide contenant des copolymères amphiphiles à base de polyéthers en combinaison avec des polymères hydrophiles
WO2007090721A1 (fr) Compositions pharmaceutiques contenant des mélanges de polymères et d'agents actifs peu solubles dans l'eau
EP2349218B1 (fr) Procédé de fabrication de formes posologiques orales à libération contrôlée
EP3337458B1 (fr) Utilisation de polymères hydrosolubles à base de n-vinylpyrrolidone et d'acide acrylique comme adjuvants pharmaceutiques
EP2863953A1 (fr) Dispersions solides renfermant des principes actifs à base de compolymères de diéthylaminoéthylméthacrylate
EP2477605A1 (fr) Préparations pharmaceutiques solides à dissolution rapide contenant des copolymères amphiphiles à base de polyéthers en combinaison avec des tensioactifs
EP2463327A2 (fr) Procédé de fabrication de granulés comprenant au moins un composant soluble dans l'eau
EP2478019B1 (fr) Granules recouvertes d'enrobages renfermant des substances actives
US20120168987A1 (en) Method For Producing Preparations Of Substances With Low Solubility In Water
WO2017032651A1 (fr) Sels de principes actifs ayant des contre-ions polymères
EP2542222A2 (fr) Formes pharmaceutiques enrobees d'une matiere fondue

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120418

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130111

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140524